Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
2021 · Cancer Discovery · 199 citations
https://doi.org/10.1158/2159-8290.cd-20-0913
A
Amir Vajdi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
109
Papers
1.4K
Citations
12
h-index
13
i10-index
Amir Vajdi is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & Lung Cancer Research Studies. The author has an h-index of 12, co-authored 93 publications.
ORCID: 0000-0001-8271-8566Papers by this author
worksCancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment
2023 · Scientific Reports · 51 citations
https://doi.org/10.1038/s41598-023-28480-9
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
2025 · Nature Medicine · 22 citations
https://doi.org/10.1038/s41591-025-03867-5
HER2 prediction from breast H&E-stained whole slide images: a comparison between ROI-based supervised learning and multiple instance learning approaches
2024 · 1 citations
https://doi.org/10.1117/12.3006884
Supplementary Figure S2 from Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938236
Data from Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7565464
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat